Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): early rheumatoid arthritis

Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): early rheumatoid arthritis - TRACER/ERA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39399

Enrollment

100

Registered

2013-05-27

Start date

2013-11-21

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Recently diagnosed reumatoid arthritis patients who have not been treated yet with disease modifying antirheumatic drugs (DMARDs).

Exclusion criteria

Exclusion criteria: - rheumatic disease, other than rheumatoid arthritis - patients previously treated with DMARDs

Design outcomes

Primary

Measure	Time frame
To test the predictive value of different tests, individually and combined, on the prognosis and respons to therapy in early reumatoid arthritis patients. - ACPA antibodies - cytokine, chemokine, adipokine profiling - (epi)genetic markers	—

Secondary

Measure	Time frame
Cost-effectiveness of these new tests and combinations of these tests to predict prognosis and response to therapy compared to existing tests like RF.	—

Countries

Netherlands

Outcome results